Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Journal"

Alimemazine: appropriate therapeutic agent for solving some difficult problems in the treatment of functional psychotic disorders (clinical cases)

M.A. Morozova, A.A. Alekseev, G.E. Rupchev
FGBNU “Scientific Center of Mental Health”, Psychopharmacology Laboratory, Moscow, Russia

Abstract: Alimemazine is antipsychotic with weak dopaminergic activity. However, it can be useful as additional agent to the basic treatment in some cases. Presented specific clinical cases demonstrate effectiveness of alimemazine in a number of clinical situations such as: change of therapy from potent dopamine blockers (neuroleptics) to atypical antipsychotic; relief of the autonomic imbalances; behavioral manifestations of psychopathic-like disorders in patients with schizophrenia and bipolar affective disorder type 1 in remission. It is assumed that the inclusion of alimemazine in therapeutic regimen can increase the quality of remission and its duration in this category of patients.

References: 
  • 1. Ibragimov D.F. Alimemazin vo vrachebnoi praktike // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2008. – T. 108, № 9. – S. 76–78.
  • 2. Timofeev N.N., Timofeeva A.N., Zamakhov Sh.M. Teralen i ego terapevticheskoe vliyanie na strukturu depressii //Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 1966. – T. 66, № 12. – S. 1855–1864.
  • 3. Zoila AF, Basset J, Lebreton M. Alimemazine tartrate (RP 6549) in psychiatric therapeutics //Presse Med. – 1959. – Vol. 67, No.23. – P. 935–936.
  • 4. Aleshina N.V. Primenenie preparata «Teralidzhen» v strukture farmakoterapii rannego detskogo autizma (protsessual'nogo i organicheskogo) // Psikhicheskoe zdorov'e. – 2014. – T. 12, № 2. – S. 70–72.
  • 5. Mnogotsentrovaya neinterventsionnaya prospektivnaya nablyudatel'naya programma izucheniya praktiki naznacheniya preparata teralidzhen u bol'nykh s diagnozom vegetativnogo rasstroistva (START-2: rossiiskii opyt primeneniya russkoyazychnoi validirovannoi versii oprosnika 4DSQ. Promezhutochnyi analiz)/ N.N.Yakhno, V.A.Parfenov, D.V.Reikhtar, A.V.Belostotskii, V.S.Arnautov // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2015. – T. 115, № 5. – S. 27–33.
  • 6. Younus M., Labellarte M.J. Insomnia in children: when are hypnotics indicated? // Paediatr Drugs. – 2002. – Vol.4, No.6. – P. 391–403.
  • 7. Klinicheskaya farmakologiya / pod red. V.G. Kukesa/ M.: Geotar-Med, 2004.
  • 8. Bekker R.A., Bykov Yu.V. Alimemazin: obzor primeneniya //Psikhiatriya i psikhofarmakoterapiya imeni P.B. Gannushkina. – 2016. – №6. – S. 10–20.
  • 9. Psikhofarmakologicheskie i protivoepilepticheskie preparaty, razreshennye k primeneniyu v Rossii / pod red. S. N. Mosolova/. M.: BINOM. 2004.
  • 10. Callaway JL, Olansky S. Trimeprazine: an adjuvant in the management of itching dermatoses //North Carolina medical journal. – 1957. –Vol. 18, No.8. – P. 320–321.
  • 11. Shamanina V.M., Zavidovskaya G.I. Terapevticheskaya otsenka teralena v klinike depressivnykh sostoyanii // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 1964. – Vyp. 2. – S. 1741–1746.
  • 12. Morozova M.A., Burminskii D.S., Rupchev G.E. Varianty dinamiki mnogoletnei lekarstvennoi remissii u bol'nykh s pristupoobrazno-progredientnoi shizofreniei: katamnesticheskoe issledovanie // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2015. – T. 115, № 7. – S. 22–29.
  • 13. Mosolov S.N., Tsukarzi E.E., Alfimov P.V. Algoritmy biologicheskoi terapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – №1. – S. 27-36.